'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Ipca Laboratories has increased 8.56% to Rs 2556.5 crore. Sales of India segment has gone up 5.65% to Rs 1,162.52 crore (accounting for 45.47% of total sales). Sales of Outside India segment has gone up 11.11% to Rs 1,393.98 crore (accounting for 54.53% of total sales). Operating profit margin has jumped from 18.75% to 21.32%, leading to 23.43% rise in operating profit to Rs 544.92 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 25.18% to 23.06%. Purchase of finished goods cost fell from 6.58% to 5.13%. Employee cost decreased from 21.80% to 21.77%. Other expenses rose from 27.57% to 28.00%.
Other income rose 6.09% to Rs 27.86 crore. PBIDT rose 22.46% to Rs 572.78 crore...
Pleaselogin & subscribe to view the full report.
More Reports
|
|